Vildagliptin in the Treatment of Type 2 Diabetes Mellitus
阅读量：
32
摘要：
Novel therapeutic approaches are continuously being researched in type 2 diabetes. The incretin class of anti-diabetic agents, consisting of glucagon-like peptide-1 agonists and dipeptidyl peptidase-4 inhibitors, has already found an important place in the current guidelines. Vildagliptin is a potent dipeptidyl peptidase-4 inhibitor, with numerous trials in type 2 diabetes treatment, both in monotherapy and in combination therapy. This review focuses on vildagliptin pharmacological properties, clinical efficacy and safety, and pharmacoeconomic data.
展开
DOI：
10.2478/rjdnmd-2013-0021
被引量：
年份：
2013
通过文献互助平台发起求助，成功后即可免费获取论文全文。
请先登入
相似文献
参考文献
引证文献
引用走势
2013
被引量：4
辅助模式
0
引用
文献可以批量引用啦~
欢迎点我试用！
